Background: Subjects with high fibroblast growth factor 21(FGF21) and 23 (FGF23), endocrine hormones that regulate insulin sensitivity and phosphate metabolism, respectively, are reported to have a higher risk for adverse cardiovascular outcome. Therefore, the relationship of FGF21, FGF23, and α-Klotho (co-receptor for FGF23 signaling) with mean platelet volume (MPV) and platelet distribution width (PDW), two platelet volume indices that reflect platelet activity, was investigated. Methods: Data from 156 patients admitted to the cardiology department were analyzed. MPV and PDW were measured by an automatic blood counter, and serum FGF21, FGF23, and α-Klotho concentrations were measured by an enzyme-linked immunoassay. Results: Log(FGF21) was significantly correlated with serum triglycerides but did not differ according to the use of non-use of antidiabetic or lipid-lowering drugs. MPV and PDW were significantly correlated (R = 0.475, p < 0.001). MPV was significantly correlated with log(FGF21) (R = -0.167, p < 0.05) and log(FGF23) (R = 0.351, p < 0.001) but not with log(α-Klotho). Linear regression analysis showed a negative and positive association of log(FGF21) and log(FGF23), respectively, with MPV that was independent of possible confounders including sex, age, renal function, and antithrombotic drug use. In addition, log(FGF23)
Introduction
Unlike other fibroblast growth factors (FGFs), FGF21 and FGF23, together with FGF19, comprise a unique subfamily that functions as endocrine hormones in the regulation of various metabolic processes [1, 2] . FGF21 is expressed predominantly in the liver, and its signaling pathway functions in adipose tissue. FGF21 is elevated in obesity and type 2 diabetes [3] and plays an important role in the regulation of insulin sensitivity and energy balance [4] . FGF23, a bone-secreted hormone, plays a crucial role in maintaining the calcium-phosphate homeostasis together with coreceptor α-Klotho, which had originally been identified as an antiaging gene [5] [6] [7] . In patients with renal failure, FGF23 is increased and α-Klotho is decreased because klotho is mainly expressed in the renal tubular epithelium [8] .
In addition to its metabolic actions, FGF23 promotes cardiac hypertrophy and fibrosis [9, 10] , which may be clinically manifested as heart failure, and left ventricular systolic and diastolic dysfunction [11] [12] [13] . Epidemiological studies demonstrated that subjects with high FGF23 are at increased risk of cardiovascular disease [14, 15] . Meanwhile, animal studies showed that FGF21 may exert cardio-protective effects [16, 17] ; in humans, however, higher FGF21 was also found to be associated with higher cardiovascular events [18, 19] , which might be related to FGF21 resistance or a compensatory elevation of FGF21 [20] .
Mean platelet volume (MPV) and platelet distribution width (PDW) are parameters of platelet volume and are considered to be useful and inexpensive-to-measure biomarkers of platelet activity [21] . MVP and PDW are reported to be increased in patients with diabetes [22, 23] and cardiovascular and cerebrovascular diseases [24] [25] [26] . To the best of our knowledge, it has not been clarified whether serum FGF21, FGF23, and/or α-Klotho concentrations are associated with the enhanced platelet activity that may underlie thromboembolic disorders. To this end, here we analyzed the relationship of FGF21, FGF23, and α-Klotho with the platelet volume indices, MPV and PDW, among cardiac patients.
Materials and methods

Study population
The current retrospective study was approved by the Ethics Committee of Osaka Medical College. Between December 2012 and December 2013, 156 cardiac patients who had provided written informed consent and for whom sufficient information regarding the data analysis for the current study was available were enrolled in the current study. ( × 0.739, when female) [27] . The patients were classified into chronic kidney disease (CKD) stages 1-5 based on eGFR levels or requirement for hemodialysis [28] . When patients had renal dysfunction with the grade of CKD stage 3 or higher, they were judged to have CKD. MPV and PDW were analyzed by automatic blood counter (ADVIA 2120i Hematology System; Siemens). Serumintact FGF23 was measured using a two-step FGF23 enzyme-linked immunosorbent assay (ELISA) kit (Kainos Laboratories, Tokyo, Japan), serum soluble α-Klotho was measured using a solid-phase sandwich ELISA kit (Immuno-Biological Laboratories, Gunma, Japan) [8] , and serum FGF21 was measured using sandwich ELISA kit (Biovendor, Modrice, Czech Republic) according to the manufacturer's instructions.
Laboratory analysis
Statistical analysis
Baseline characteristics were assessed with standard descriptive statistics. Data were expressed as either mean±standard deviation or median and interquartile range. Pearson and Spearman correlation tests were used to assess the correlation between two variables when variables were normally and non-normally distributed, respectively. 
Results
Patient characteristics
Among the 156 patients enrolled, 108 (69%) were male and 15 (9.6%) had severe renal dysfunction (CKD stage 4 or 5) ( Table 1 ). Ischemic heart disease was the most prevalent underlying cardiac disorder, and about twothirds and one-third of patients, respectively, were taking antiplatelet drugs and anticoagulants. Log(FGF21) was associated borderline significantly with CRP (R = 0.145, p = 0.071) and significantly with triglycerides (R = 0.196, p = 0.014) and log(α-Klotho) (R = -0.164, p = 0.041); meanwhile, log(FGF21) was not significantly correlated with age, body mass index, systolic blood pressure, fasting glucose, or eGFR. The FGF21 levels did not significantly differ according to the use or non-use of insulin, sulfonylurea, dipeptidyl peptidase 4 (DPP-4) inhibitors, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, or statin (data not shown). Among metabolic data, fasting glucose was significantly correlated with PDW (R = 0.182, p = 0.026). Among 149 patients for whom HbA 1c data were available, HbA 1c had a significant correlation with MPV (R = 0.182, p = 0.026) and PDW (R = 0.170, p = 0.038). HbA 1c was also associated significantly with log(FGF23) (R = 0.182, p = 0.027) and borderline significantly with log(FGF21) (R = -0.148, p = 0.071).
Relationship between MPV and FGF21, FGF23, and α-Klotho
MPV was significantly correlated negatively with log(FGF21) and positively with log(FGF23) (Figure 1 ).
Although MPV and PDW were significantly correlated (R = 0.475, p < 0.001), the association between PDW and log(FGF21) or log(α-Klotho) was found to be non-significant (Figure 2 ). When the data were assessed in tertiles of FGF21 and FGF23, the mean MVP value seemed to decrease and increase, respectively, with higher tertiles of log(FGF21) and log(FGF23) ( Figure 3A ). This tendency was not observed for the mean PDW value ( Figure 3B) .
In univariate linear regression analysis, age, log(FGF21), and log(FGF23) were found to have a significant association with MPV ( Table 2) . We used antithrombotic drugs as a possible independent variable because several previous reports have shown a relationship between such drugs and platelet indices [29, 30] . In the multivariate model, the relationship of FGF21 and FGF23 with MPV remained significant after taking antithrombotic drug use into account (Table 2 ). In the stepwise multivariate analysis performed by entering variables that were used in univariate analysis, the association of MVP with log(FGF21) and log(FGF23) retained statistical significance. When PDW was used as the dependent variable in the same multivariate model, log(FGF23), but not log(FGF21), was found to be a significant factor. Then we analyzed the patient with (n = 119) or without (n = 37) CKD. When only patients with CKD were analyzed, stepwise regression analysis showed that log(FGF23) was, but log(FGF21) was not, selected as a factor that had significant association with MPV with standardized correlation coefficient of 0.36 (p < 0.001). Meanwhile, neither log(FGF21) or log(FGF23) had significant association with PDW (data not shown). When only patients without CKD was analyzed, neither log(FGF21) nor log(FGF23) was selected as significant predictor for MPV (data not shown). Meanwhile, log(FGF23) was selected as a factor that had significant association with PDW with standardized correlation coefficient of 0.34 (p = 0.039).
Discussion
We demonstrated that FGF21 and FGF23, respectively, were negatively and positively associated with MPV, a biomarker of platelet activity, independent of sex, age, blood pressure, antithrombotic use, renal function, fasting glucose, and triglycerides. FGF23 also had a positive association with PDW. α-Klotho did not have a significant association with MPV or PDW. Higher FGF21 was independently associated with lower MPV, suggesting lower platelet activity among patient with relatively higher levels of FGF21.
Until now, the risk of thrombotic diseases in terms of serum FGF23 has not been specifically addressed. An association between FGF23 and the platelet activity markers, MPV and PWD, if present at all, may have several physiological consequences. First, considering that FGF23 increases with advancement of renal dysfunction [8] and MPV is reported to increase with progression of CKD [31] , FGF23 might be involved in the increased risk of systemic thromboembolism seen among patients with CKD [32] . In the current study population, however, neither MPV nor PDW was associated with renal function (CKD stage), which might be related to the fact that patients with severe renal dysfunction (CKD stages 4/5) comprised < 10% of the study population (Table 2 ). Second, low bone mineral density (BMD) has been reported be associated with high MPV [33] and increased risk of thromboembolic diseases [34] . Considering that FGF23 is involved in bone mineral metabolism, FGF23 might be involved in the increased thromboembolic risk in osteoporosis. Because the reported association between FGF23 and BMD seems to vary according to the study population [35, 36] , BMD should also be quantified among cardiac patients.
Little information is available about the relationship between serum FGF21 and thromboembolic risk, although high FGF21 levels have been found to be associated with cardiovascular disease and stroke [19] . Several recent studies showed that adiponectin is inversely associated with platelet activation [37, 38] . FGF21 might increase with adiponectin [39] , although the relationship may not be straightforward [40, 41] . To examine the possibility that adiponectin, but not FGF21, is associated inversely with MPV in the study population, circulating adiponectin levels should be assessed in future studies.
There are several limitations to the current study. First is the heterogeneity of the study population: the patients enrolled had various cardiovascular conditions and were taking various drugs that may potentially alter the FGF21/ FGF23 and α-Klotho concentrations and platelet activity. Second, the cross-sectional nature of the study means that whether modulation of FGF21/FGF23 and α-Klotho may have therapeutic implications cannot be concluded. A third limitation is the relatively small sample number. Log(FGF23), but not log(FGF21), was independently associated with PDW among patients without CKD and with MPV among patients with CKD. However, the number of CKD (n = 119) and non-CKD (n = 37) subjects were small; therefore, whether relation between FGF21/FGF23 and platelet indices really differ according to the CKD status should be analyzed in future studies. Fourth, we did not assess the expression of β-Klotho, which may act as a coreceptor for FGF21 signaling.
In summary, cardiac patients with higher serum FGF23 and lower FGF21 levels had high MPV, and presumably increased platelet activity, and this relationship was independent of sex, age, fasting glucose, triglycerides, and renal function. Future studies of high FGF23 and low FGF21 serum levels and the incidence of thromboembolic disorders are warranted.
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